Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
Pharma Marketing News e-Newsletter | Subscribe | Pharma Marketing Online Discussion Forum
Reports | Resources/Links | Glossary | Case Studies | Surveys | Pharma Marketing Blog
Pharma Marketing Vendor Directory | Conference Calendar | Pharma Jobs
Advertising Information | FAQs | About Us | Privacy Policy
| Also see Pharma Marketing News OpEd Pieces |
Does the FDA Need to be Overhauled?
Posted: January 13, 2005The Vioxx withdrawal put the Food and Drug Administration (FDA) under the spotlight. There were allegations that the FDA was in cahoots with Merck in keeping Vioxx problems under wraps (see, for example, Will COX-2 Inhibitors Crash and Burn?). A New York Times story reported "Members of Congress, an internal F.D.A. whistleblower and prominent medical journals have said the agency is incapable of uncovering the perils of drugs that have been approved and are in wide distribution."Other critics, such as Dr. Angell (see "The Truth About the Drug Companies: What To Do About It"), have broader issues with the FDA. Among the suggestions for revamping the FDA are the following: